{'fraction_non_alphanumeric': 0.012612612612612612, 'fraction_numerical': 0.0018018018018018018, 'mean_word_length': 5.385057471264368, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The Current Evolutions in the Pharmacotherapeutic Management of Heart Failure

The heart failure remains as global pandemic, more than 23 million people are suffering from heart failure worldwide. The morbidity, mortality and economic burden are increasing rapidly day by day. In order to overcome this situation novel therapies to be developed to treat the heart failure. Many novel therapies accomplished all phases of clinical trials and ruling the pharmaceutical market such as sacubitril valsartan with a positive outcome on heart failure. Some new promising potent compounds such as vericiguat, omecamtiv mecarbil proved themselves by reducing HF complications. In addition, researchers are working very keenly in order to develop to new drug therapies for heart failure. In recent days, many new clinical instances have reported in development of drugs mainly to manage HF patients with mid-range and preserved left ventricular ejection fraction. This article targets to review the Current evolutions in the pharmacological plan of heart failure and focuses on the emerging potential therapeutic agents.